Boustead healthcare unit acquires majority stake in medtech company via S$6 million equity injection featuring UroMedTech
Post-acquisition, UroMedTech will continue to operate under its existing brand
[SINGAPORE] Boustead Singapore : F9D 0% unit Boustead Medical Care Holdings (BMCH) has acquired a 60 per cent stake in a urology robotics company through a S$6 million equity injection, the engineering and technology group said on Friday (Jul 3).
BMCH, which falls under Boustead’s healthcare division, focuses on rehabilitation robotics, digital healthcare and medical innovation.
Singapore-based UroMedTech is known for pioneering robotic solutions for prostate cancer diagnosis through its UroMaster system. Its R&D road map includes integrating focal therapy treatment, a minimally invasive method to target tumours, within UroMaster.
